<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00698490</url>
  </required_header>
  <id_info>
    <org_study_id>208141/015</org_study_id>
    <nct_id>NCT00698490</nct_id>
  </id_info>
  <brief_title>Humoral and Cellular Immune Response of Herpes Simplex (gD) Candidate Vaccines From 2 Different Cell Lines</brief_title>
  <official_title>Study to Compare, in Healthy HSV Seronegative and HSV Seropositive Subjects, the Humoral and Cellular Immune Response of Herpes Simplex Candidate Vaccines Containing gD From Two Different Cell Lines and Using gD-Alum as Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare, in healthy HSV seronegative and HSV seropositive
      subjects, the humoral and cellular immune response of herpes simplex candidate vaccines
      containing gD from two different cell lines and using gD-Alum as control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At the time of conduct of this study, the sponsor GlaxoSmithKline was known by its former
      name SmithKline Beecham.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1995</start_date>
  <completion_date type="Actual">January 1997</completion_date>
  <primary_completion_date type="Actual">January 1997</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate in initially HSV-seronegative subjects the GMT's and the seroconversion rates of anti-gD2 antibodies (ELISA)</measure>
    <time_frame>After the second and third doses of each vaccine</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate in initially HSV-seronegative subjects, the GMT and the seropositivity rate of anti-HSV-2 neutralizing antibodies</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the cell-mediated immune (CMI) response (lymphoproliferation, secretion of interleukin 2 and Î³ interferon)</measure>
    <time_frame>After the second and third dose of each vaccine formulation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate, in initially seronegative subjects and in initially seropositive subjects, the incidence and intensity of solicited local and general signs and symptoms</measure>
    <time_frame>During 3 days after each dose of each vaccine</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate in initially seropositive subjects, the GMT and the seropositivity rate of anti-gD2 antibodies (ELISA) and of anti-HSV-2 neutralizing antibodies</measure>
    <time_frame>After 2 and 3 doses of vaccines</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Prophylaxis Herpes Simplex</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HSV-seronegative subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HSV-seropositive subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HSV-seronegative subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HSV-seronegative subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HSV-seronegative subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adjuvanted herpes simplex (gD) candidate vaccine GSK 208141</intervention_name>
    <description>Intramuscular injection, 3 doses, 2 different formulations</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Herpes simplex virus containing gD-Alum</intervention_name>
    <description>Intramuscular injection, 3 doses</description>
    <arm_group_label>Group E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between 18 and 45 years of age

          -  Written informed consent

          -  Female volunteers must be using contraception and should avoid becoming pregnant for
             the duration of the vaccination course

          -  Serology: Groups 1, 3, 4 and 5: HSV-1 AND HSV-2 seronegative (by gD2 ELISA); Group 2:
             HSV seropositive by gD2 ELISA before entry

        Exclusion Criteria:

          -  Any previous vaccination against Herpes simplex.

          -  Any previous administration of MPL.

          -  Pregnancy or lactation.

          -  Patient is immuno-compromised or is receiving immuno-modifying therapy of any kind.

          -  Clinical signs of acute or febrile illness at the time of entry into the study.

          -  Any administration of immunoglobulins during the vaccination course or within one
             month of vaccination.

          -  Any vaccination within one week of study vaccination.

          -  Previous known hypersensitivity to vaccination or to any component of the vaccine.

          -  Simultaneous participation in any other clinical trial with an investigational drug or
             vaccine. Subjects currently in a follow-up period of a vaccine study can be included.

          -  Recent history of alcoholism or drug abuse (within the past 6 months).

          -  Life-threatening or serious cardiac (NYHA grades III-IV), gastrointestinal, hepatic,
             renal, hematological or immunological disorder which, in the opinion of the
             investigator, would preclude entry into the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Clinical Trials Call Center</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2008</study_first_submitted>
  <study_first_submitted_qc>June 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2008</study_first_posted>
  <last_update_submitted>June 16, 2008</last_update_submitted>
  <last_update_submitted_qc>June 16, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2008</last_update_posted>
  <responsible_party>
    <name_title>Isabelle Harpigny</name_title>
    <organization>GSK</organization>
  </responsible_party>
  <keyword>Herpes simplex</keyword>
  <keyword>Herpes simplex candidate vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Simplex</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

